ArticleDiscover oncology2026
Lung cancer therapy using a chitosan-based nano drug discovery system of silver nanoparticles and chemotherapeutics.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is the leading cause of cancer-related mortality among various types of cancer. In this way, unfortunately, some conventional modalities in cancer treatment such as surgery, immunotherapy, chemotherapy, etc., have high levels of deficiencies and even they can lead to death. To solve this challenge, this paper aims to develop a novel technology such as drug delivery systems (DDSs) based on nanoparticles (NPs).
methodsTo do so, chitosan (CS)-polycaprolactone (PCL) NPs were fabricated for efficient silver (Ag) NPs and sodium butyrate (NB) delivery to A549 lung cancer cells. Then, the CS-PCL-Ag-NB sample was characterized using FT-IR, DLS, TEM, and TGA devices. The quality of the syntheses verified, the size determined at about 100 nm to 20 nm in diameter, high thermal stability determined, and 30% Ag and 8% NB contents were measured for CS-PCL-Ag-NB.
resultsAccording to the obtained results, the controlled (eight folds slower compared with pure NB) and pH-sensitive (3 folds faster in pH 5.0) NB releases were observed for nanocarrier. Moreover, the cell viability assay demonstrated more than 75% cytotoxicity for CS-PCL-Ag-NB after 24 h treatment with 20 nM concentration. Furthermore, qRT-PCR technique exhibited a 9.6, 5.9, and 7.8 folds increase in the expression levels of Caspase9, Bax, and P53 apoptotic genes after treatment with CS-PCL-Ag-NB.
conclusionHigh biocompatibility obtained for CS and CS-PCL samples. CS-PCL-Ag-NB indicated higher cancer cell inhibition potency compared with pure NB while fabricated nanocarrier had very low toxicity on MSC normal cells. Finally, the obtained results confirmed the ability of CS-PCL-Ag-NB in suppressing cancer cells and inducing apoptosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.